Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4978998 | 0.94 | SLC1A2 (0.32) | SLC1A2SLC1A1LMNATSHR | |
| SCHEMBL1616452 | 0.82 | MAPT (0.31) | GAA | |
| SCHEMBL1616226 | 0.79 | GLI1 (0.33) | — | |
| SCHEMBL9610 | 0.78 | ATM (0.33) | ALDH1A1LMNATSHR | |
| SCHEMBL1617311 | 0.77 | HPGD (0.43) | ALDH1A1LMNATSHRKMT2A | |
| SCHEMBL5025712 | 0.74 | HSD11B1 (0.31) | HSD11B1SLC1A2SLC1A1LMNATSHR | |
| SCHEMBL1616601 | 0.74 | MAPT (0.50) | ALDH1A1LMNATSHR | |
| SCHEMBL6221348 | 0.74 | POLB (0.31) | GAA | |
| SCHEMBL727442 | 0.74 | ALDH1A1 (0.40) | ALDH1A1LMNAKMT2A | |
| SCHEMBL20303774 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012030952-A3 | REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY | TEXAS INSTRUMENTS INCORPORATED (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20110295038-A1 | Process for the Preparation of Substituted 1-aminomethyl-2-phenyl-cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295038-A1 | Process for the Preparation of Substituted 1-aminomethyl-2-phenyl-cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295038-A1 | Process for the Preparation of Substituted 1-aminomethyl-2-phenyl-cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| WO-2011147576-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 1-AMINOMETHYL-2-PHENYL-CYCLOHEXANE COMPOUNDS | Grünenthal GmbH (DE) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147576-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 1-AMINOMETHYL-2-PHENYL-CYCLOHEXANE COMPOUNDS | Grünenthal GmbH (DE) | 2011-12-01 | — | — | WO | disclosed |
| EP-2231629-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-7923450-B2 | Modulators for amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-2231629-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
| WO-2002028183-A1 | FUNGICIDES | SYNGENTA LIMITED (GB) | 2002-04-11 | — | — | WO | disclosed |
| US-5527805-A | DNA-CLEAVING, CYTOTOXIC AND ANTI-TUMOR COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-06-18 | — | — | US | disclosed |
| US-5281710-A | Antibiotics or antitumor agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-25 | — | — | US | disclosed |
| US-5276159-A | Antitumor | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | PARP1, PARP11, PARP2 | HSD11B1 1331/4885ALDH1A1 420/4885SLC1A2 2882/4885 |
| US-20090181965-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, BACE1 | HSD11B1 266/4885ALDH1A1 3574/4885SLC1A2 1436/4885 |
| US-20110295038-A1 | Process for the Preparation of Substituted 1-aminomethyl-2-phenyl-cyclohexane Compounds | ADRM1, PNMT, ACMSD | HSD11B1 2394/4885ALDH1A1 1163/4885SLC1A2 1398/4885 |
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | HSD11B1 1492/4885ALDH1A1 4674/4885SLC1A2 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.